HIV Infections - Drug therapy
Research News and Information

Saturday, November 21, 2009

Transmission of drug-resistant HIV-1 is stabilizing in Europe.

13 Nov 2009 The SPREAD Programme investigated prospectively the time trend from September 2002 through December 2005 of transmitted drug resistance (TDR) among 2793 patients in 20 European countries and in Israel with newly diagnosed human immunodeficiency ... Read more...

Postnatal HIV-1 transmission after cessation of infant extended antiretroviral prophylaxis and effect of maternal highly active antiretroviral therapy.

13 Nov 2009 BACKGROUND: The association between postnatal human immunodeficiency virus type 1 (HIV-1) transmission and maternal highly active antiretroviral therapy (HAART) after infant extended antiretroviral prophylaxis was assessed. METHODS: A follow-up ... Read more...

Effect of baseline CD4 cell counts on the clinical significance of short-term immunologic response to antiretroviral therapy in individuals with virologic suppression.

30 Oct 2009 BACKGROUND: Achieving virologic suppression is a clear therapeutic goal for patients receiving combination antiretroviral therapy (cART). However, the effects of immunologic responses, whether measured as CD4 count changes from baseline or CD4 ... Read more...

Latest indexed articles for 'HIV Infections - Drug therapy'

These are the very latest articles for this heading:

• HIV/AIDS and diabetes: minimizing risk, optimizing care. 29 Nov 2009
• Nanotechnology for antiretroviral drug delivery. 29 Nov 2009
• Transmission of drug-resistant HIV-1 is stabilizing in Europe. 13 Nov 2009
• Postnatal HIV-1 transmission after cessation of infant extended antiretroviral prophylaxis and effect of maternal highly active antiretroviral therapy. 13 Nov 2009
• Strategic approaches to decrease breast milk transmission of HIV-1: the importance of small things. 13 Nov 2009
• Effect of baseline CD4 cell counts on the clinical significance of short-term immunologic response to antiretroviral therapy in individuals with virologic suppression. 30 Oct 2009
• Raltegravir, etravirine, and ritonavir-boosted darunavir: a safe and successful rescue regimen for multidrug-resistant HIV-1 infection. 30 Oct 2009
• Gender differences in discontinuation of antiretroviral treatment regimens. 30 Oct 2009
• Minority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: implications for the use of second-generation nonnucleoside reverse transcriptase inhibitors. 30 Oct 2009
• Prevention of mother-to-child transmission of HIV-1 through breastfeeding by treating mothers with triple antiretroviral therapy in Dar es Salaam, Tanzania: the Mitra Plus study. 30 Oct 2009
• The association between food insecurity and mortality among HIV-infected individuals on HAART. 30 Oct 2009
• Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection. 30 Oct 2009
• Is 1 alanine transaminase >200 IU enough to define an alanine transaminase flare in HIV-infected populations? A new definition derived from a large cohort study. 30 Oct 2009
• Tenofovir coadministration is not associated with lower unboosted atazanavir plasma exposure in the clinical setting. 30 Oct 2009
• Increased peripheral proinflammatory cytokines in HIV-1-infected patients with prolonged viral suppression suffering from high psychological stress. 30 Oct 2009
• Universal access not a dream. 30 Oct 2009
• HIV drug patents in the spotlight. 30 Oct 2009
• Mobilising the community in the fight against HIV/AIDS. 29 Oct 2009
• Barriers to the care of HIV-infected children in rural Zambia: a cross-sectional analysis. 14 Oct 2009
• Efficacy and safety of pegylated interferon plus ribavirin in HIV and hepatitis C virus-coinfected patients with advanced immunosuppression. 13 Oct 2009

See a longer list of these articles.

Technical information about 'HIV Infections'

Definition: Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).

Descriptor UI: D015658

Alternative terms: HIV Infections; HIV Infection; Infection, HIV; Infections, HIV; HTLV-III-LAV Infections; HTLV III LAV Infections; HTLV-III-LAV Infection; Infection, HTLV-III-LAV; Infections, HTLV-III-LAV; T-Lymphotropic Virus Type III Infections, Human; T Lymphotropic Virus Type III Infections, Human; HTLV-III Infections; HTLV III Infections; HTLV-III Infection; Infection, HTLV-III; Infections, HTLV-III;

Related Mesh Headings: Lymphoma, AIDS-Related;

Allowable Qualifiers: blood; cerebrospinal fluid; chemically induced; classification; complications; congenital; diagnosis; diet therapy; drug therapy; economics; embryology; enzymology; ethnology; etiology; genetics; history; immunology; metabolism; microbiology; mortality; nursing; epidemiology; parasitology; pathology; physiopathology; prevention & control; psychology; radiography; radionuclide imaging; radiotherapy; rehabilitation; surgery; therapy; transmission; urine; veterinary; ultrasonography; virology;

Tree Number: C02.782.815.616.400; C02.800.801.400; C20.673.480;

Online Note: use ACQUIRED IMMUNODEFICIENCY SYNDROME to search HUMAN T-LYMPHOTROPIC VIRUS TYPE III INFECTION 1989; HIV INFECTION 1988-89; HTLV-III INFECTION & HTLV-III LAV INFECTION 1987-89

History Note: 90; T-LYMPHOTROPIC VIRUS TYPE III INFECTION, HUMAN was HUMAN T-LYMPHOTROPIC VIRUS TYPE III INFECTION see ACQUIRED IMMUNODEFICIENCY SYNDROME 1989; HIV INFECTION was see ACQUIRED IMMUNODEFICIENCY SYNDROME 1988-89; HTLV-III INFECTION & HTLV-III-LAV INFECTION were see ACQUIRED IMMUNODEFICIENCY SYNDROME 1987-89

Technical Notes: caused by a lentivirus; GEN or unspecified; coord IM with HIV-1 (IM) or HIV-2 (IM); note specific indentions under HIV INFECTIONS; DF: HIV INFECT